I think it will all go down to weight the risks and the benefits of when to take it. In 2018, the first LNP medication was approved and I think it's important to look at articles after this year. Partisiran has shown amazing results for the patients with transthyretin-related amyloidosis ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653129/ , https://pubmed.ncbi.nlm.nih.gov/33212063/ , https://pubmed.ncbi.nlm.nih.gov/30586695/)
Although it is a rare disease, these patients are taking injections every 3 weeks since 2018 so it is interesting to observe their progression. As more of these types of medications will be approved, it sure will increase the information available, and for sure it is important to be critic and continue the surveillance, the same as with all the medications available in the market.
spore / Spore
npub1d2…hrmup
2023-02-07 21:58:02
in reply to nevent1q…ve9r
Author Public Key
npub1d28y5g76rt8r5d5slw03akyht2t8ay3jaxhhqr0620ngjma50pxq5hrmupPublished at
2023-02-07 21:58:02Event JSON
{
"id": "4346be0ae331ceb5a6c4e226bfd27a75fc3ca30e0f4d609c982e74d62d4989f6",
"pubkey": "6a8e4a23da1ace3a3690fb9f1ed8975a967e9232e9af700dfa53e6896fb4784c",
"created_at": 1675807082,
"kind": 1,
"tags": [
[
"e",
"2a7fb55c14defeaa80f3edd5dc08d6f1e03cb881629a45edcf1b145e99d00ee0",
"wss://bitcoiner.social",
"root"
],
[
"p",
"803a613997a26e8714116f99aa1f98e8589cb6116e1aaa1fc9c389984fcd9bb8"
],
[
"e",
"9fa24c6624f4c2d8aab3f9b2a9abc8d09f5eedd744501d5b8a1ca0b36a9470e1",
"wss://bitcoiner.social",
"reply"
]
],
"content": "I think it will all go down to weight the risks and the benefits of when to take it. In 2018, the first LNP medication was approved and I think it's important to look at articles after this year. Partisiran has shown amazing results for the patients with transthyretin-related amyloidosis ( https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653129/ , https://pubmed.ncbi.nlm.nih.gov/33212063/ , https://pubmed.ncbi.nlm.nih.gov/30586695/)\nAlthough it is a rare disease, these patients are taking injections every 3 weeks since 2018 so it is interesting to observe their progression. As more of these types of medications will be approved, it sure will increase the information available, and for sure it is important to be critic and continue the surveillance, the same as with all the medications available in the market.",
"sig": "69bdb435d52a2d50a1ff533217dc9e318e54bb0d403f1e791ff84e4cce12cb7285249511a087f4d83732781b68fb309c12679c103b3d361b9ff623b160561b39"
}